Peter O'Donnell is a freelance journalist who specializes in European health affairs and is based in Brussels, Belgium.
EMA: A Change in Character as Well as Powers?
Increased public engagement leads recent change in EMA profile.
A Breakthrough or A Breakdown for Health Technology Assessment in Europe?
The European Union has at last agreed on how HTA should be coordinated among Europe's multiple HTA agencies, bringing to an end a three-year process of discussion.
European Drug Repurposing: An Update
European authorities have announced a proposal for a framework to support not-for-profit organizations and academia in repurposing authorized medicines.
Is Personalized Medicine Finally Gaining Traction in Europe?
A new straw has appeared in the wind that may mean something more substantial will emerge than the customary rhetoric...
Sharing COVID Vaccine Know-How: A New Twist on a Long-Running Debate
A proposal to address inequities in access to critical COVID vaccine commodities is still deadlocked a year after it was submitted.
Multi-million European Contracts Up for Grabs for Developing Antibiotics
The EU is offering some $13 million for advice on bringing to the market medicines that combat antimicrobial resistance—and there's only one month to claim the grant...and then nine to do the work.
Europe Seeking Clarity in Complex Clinical Trials
Pandemic sparks new advancements in clinical trial development.
Rhetoric and Realism Colliding on EU Discussions of Drug Repurposing
Slovenia brings EU health officials together for increased emphasis on repurposing.
NICE Consults On Its New Assessment Scheme Amid A Blizzard Of Spin
Promises of "more equitable access for those with severe diseases," "decision-making flexibility where it counts," and more in a bid to win post-Brexit business.
HERA, A Matriach's Device to Save Europeans from the Next COVID
European Commission proposes new bio-defense preparedness plan.
Obligatory Summertime Reading–How to Use the EU's New Clinical Trials Regulation
Faint Ripples of Support Detected in Europe for High-Tech Drug Development
A draft report from parliament's cancer committee highlights the benefits that precision and personalized medicine offer.
Convergent Drivers of European Medicines Policy
Not just COVID is changing the landscape of pharmaceutical policy in Europe.
Putting the Squeeze on Trial Reporting Failings in Europe
Allegedly more than 4,000 clinical trials of medicines are missing results on the European trial registry, in violation of transparency rules.
Closer European Collaboration on the Ground on HTA and Marketing Authorization—But Under a Political Cloud
A new report from the EMA and EUnetHTA shows a shift towards a more efficient form of collaboration.
Is COVID A Game-Changer for Wider Drug Development Policy?
Conclusions from the Global Health Summit provide plenty of support for research, innovation, investment, and incentivization.
A Quiet International Revolution in Clinical Trial Regulation
A major international collaboration within ICH features big hitters from across the world's major regulatory authorities and drug firms
Exploiting Research Infrastructures for Personalized Medicine in Europe
The EU Cancer Research Summit sparked powerful support for personalized and precision medicine across three specific areas of research: translational, clinical, and outcomes.
New Structures to Tackle New Challenges in European Healthcare
Pressure mounts in Brussels as calls for new ways to debate pharma policies come from all directions.
Dragging the EU into a More Health-Conscious Post-COVID Dynamic
Parliament's health committee is answering calls for a firmer grip on policies affecting the well-being of its 450 million citizens.
Europe's Eternal Struggle with Safety and Innovation
European Group on Ethics in Science and New Technologies issues cautious opinion on the use of gene editing amidst COVID vaccination controversy.
Another European Gap that Needs to be Filled: Advanced Diagnostics
Rate of adoption in Europe for advanced diagnostics is falling behind that of others' globally.
Personalized Medicine Yet Again Expecting a European Boost
A new partnership, to be known as EP PerMed, aims to bring public and private sector interests together.
Can Europe Solve its Own Drug Pricing Dilemmas?
Upcoming study reveals challenges faced by Europe over the pricing of pharmaceuticals.
Europe's Leaders Still Discussing How to Respond to the COVID Pandemic
The latest initiative against COVID, the European Health Emergency Preparedness and Response Authority, is taking shape with intentions of revealing the vulnerabilities in global supply chains and more.
HTA—Easier to Reach Global Consensus Than an Agreement in Europe
After three years, member states of the EU have yet to make any real progress on legislation that would coordinate their clinical assessments more closely.
EMA’s Cooke Reviews European Cancer Prospects
Cancer still a primary focus of EMA in light of COVID and vaccine development.
Beating Cancer in Europe—And Beating Some of The Discrimination That Cancer Generates
The $4 billion program will embrace the disease's entire pathway, from prevention to quality of life of patients and survivors.
Battling COVID on the Policy Front in Europe
After issuing a conditional marketing authorization issued just a week ago for the Moderna vaccine and receiving applications for more, the EU has reserved vaccines sufficient to treat more than 80% of the European population.
Three Kings Come Through with Another COVID Vaccine for Europe
As the EMA gives Moderna's COVID vaccine the thumbs up, the European Commission has quickly followed up with its own approval.
2 Commerce Drive Cranbury, NJ 08512